About / Ronald R

Ronald R covers the GLP-1 and metabolic-medicine beat: what these drugs are approved for, what the trials actually measured, what the labels say, what they cost, and how supply and policy keep moving underneath all of it.

He works from primary documents — prescribing information, trial registries, regulatory notices, company statements — and dates every figure, because a price or a shortage that was true last quarter frequently is not.

He does not give medical advice, and does not tell readers what to take.

Written by Ronald R

• Wegovy vs Mounjaro: A Weight-Loss Drug, a Diabetes Drug, and the Trial That Compared Neither

  2026-10-20

• Metsera: How Pfizer Bought Its Way Back Into Obesity Drugs, and What Is Now in Trials

  2026-10-20

• Ozempic Body: What 'Ozempic Butt', Feet and Hands Describe, and What Has Actually Been Measured

  2026-10-20

• Ozempic Teeth: No Label Lists It, No Trial Has Measured It, and What the Record Does Show

  2026-10-20

• Wegovy Weight Loss Results: Every STEP Trial, the 7.2 mg Dose, and What Happened After Stopping

  2026-10-20

• Victoza vs Ozempic: What SUSTAIN 10 Measured Head to Head, and What the Two Labels Add

  2026-10-17

• GLP-1 Drugs and Kidney Disease: What FLOW Found, Ozempic's Kidney Indication, and the Acute Kidney Injury Warning

  2026-10-17

• GLP-1 Drugs for Prediabetes: What Three Trials Measured on Progression to Diabetes, and Why No Label Covers It

  2026-10-17

• Acid Reflux and Heartburn on Zepbound, Wegovy, Ozempic and Mounjaro: The Label Rates, the Cohort Studies, and the One pH Trial

  2026-10-17

• Xultophy 100/3.6: Novo Nordisk's Insulin Degludec and Liraglutide Pen, Its Six Trials, and Where It Stands in 2026

  2026-10-17

• Bimagrumab: What Lilly's Muscle-Sparing Antibody Did Alongside Semaglutide, Arm by Arm

  2026-10-15

• Does Medicare Cover GLP-1 Drugs? Zepbound, Wegovy, Ozempic and the Rest, Brand by Brand

  2026-10-15

• GLP-1 Drugs for Teens: Which Are Approved, From What Age, and What the Adolescent Trials Recorded

  2026-10-15

• "Ozempic Personality": What the Record Shows About GLP-1 Drugs, Pleasure and Motivation

  2026-10-15

• Zepbound Weight Loss Results: Every SURMOUNT Trial, What It Measured and What People Lost

  2026-10-15

• Eloralintide: What Lilly's Amylin Drug Did in Its 48-Week Trial, and the Five Phase 3 Studies Now Running

  2026-10-14

• Exenatide (Byetta, Bydureon): The First GLP-1 Drug, Its Trials, and Why No US Product Is Listed as Marketed Today

  2026-10-14

• Food Noise: What It Means, How Researchers Now Measure It, and What GLP-1 Studies Have and Have Not Shown

  2026-10-14

• Soliqua: The Insulin-and-GLP-1 Pen, What Its Trials Showed, and How It Differs From Ozempic

  2026-10-14

• Zepbound Vials: Which Strengths Exist, What They Cost at LillyDirect, and How They Differ From the Pen and KwikPen

  2026-10-14

• The Gila Monster and GLP-1 Drugs: What Came From Lizard Venom, What Did Not, and Why Ozempic Is Not Made From It

  2026-10-14

• GLP-1 Constipation: The Rate in Every Current Label, the Placebo Rate Beside It, and Why Episodes Last Weeks Rather Than Days

  2026-10-11

• GLP-1 Headache: What the Zepbound, Wegovy, Ozempic and Mounjaro Labels Record, How Much of It Placebo Matched, and Why Neurologists Are Testing These Drugs for Headache

  2026-10-11

• GLP-1 Injection-Site Reactions: Rates on Zepbound, Wegovy, Ozempic, Mounjaro and Saxenda, and the Antibody Link the Tirzepatide Labels Report

  2026-10-11

• Sulfur Burps on Zepbound, Wegovy, Ozempic and Mounjaro: What the Labels Call Them, How Often Trials Recorded Them, and What No Study Has Tested

  2026-10-11

• GLP-1 Patient Assistance Programs in 2026: Which Drugs Novo Nordisk and Lilly Give Free, and the Income Lines They Print

  2026-10-09

• Mounjaro for Weight Loss: What Its Diabetes Trials Measured, and Why Zepbound Is the Same Drug With a Weight Label

  2026-10-09

• GLP-1 Diarrhoea: How Often It Happens on Zepbound, Wegovy, Ozempic and Mounjaro, How Much Is the Drug, and How Long Episodes Last

  2026-10-11

• Ozempic and Vision Loss: What Regulators Have Said About NAION, What the Studies Measured, and Why US Labels Still Say Nothing

  2026-10-09

• Victoza: Novo Nordisk's Daily Liraglutide for Type 2 Diabetes, Its Eight Generic Copies, and a Shortage Entry Still Open

  2026-10-09

• How Long Do GLP-1 Side Effects Last? Episode Length, the Escalation Peak, a 12-Month Curve and the Weeks After the Last Dose

  2026-10-06

• Ozempic for Weight Loss: What the Label Approves, What Its Diabetes Trials Measured, and Why Wegovy Exists

  2026-10-06

• Ozempic Savings Card 2026: The $25 Offer, Its $100 Cap, the Tablets It Now Covers and the $499 Self-Pay Pen

  2026-10-06

• Trulicity (Dulaglutide): What the 2026 Label Approves, the Heart Trial Behind It, Side-Effect Rates and the Savings Card

  2026-10-06

• Where to Get the Wegovy Pill: CVS, Costco, Amazon, NovoCare and Telehealth, Compared From Their Own Pages

  2026-10-06

• Mazdutide: The Glucagon/GLP-1 Drug Approved in China but Not the US — Its Trials, Its Two Owners, and Lilly's 16 mg Result

  2026-10-05

• Saxenda: Novo Nordisk's Daily Liraglutide for Weight, Its Generic Copies, and the Discontinuation Notice in FDA's Shortage Database

  2026-10-05

• Survodutide: Where Boehringer Ingelheim's Glucagon/GLP-1 Drug Stands — Two Obesity Trials Published, a Heart Trial Finished Without Results, and No Filing Yet

  2026-10-05

• What Is Mounjaro? Eli Lilly's Diabetes Brand of Tirzepatide, Its Two Approved Uses and the Two 2026 Changes to Its Label

  2026-10-05

• What Is Ozempic? Novo Nordisk's Diabetes Brand of Semaglutide, Its Three Approved Uses and How Its Label Grew, From FDA's Records

  2026-10-05

• Ozempic, Zepbound and Breastfeeding: What the Labels and the Milk Studies Actually Measured

  2026-10-04

• Wegovy Savings Card 2026: The $25 Offer's $100 Cap, the Tablet Version and the Annual Limit It Mentions but Never States

  2026-10-04

• What Is Wegovy? Novo Nordisk's Semaglutide Brand, Its Four Approved Uses and Its Five Forms, From FDA's Records

  2026-10-04

• When Will Tirzepatide Go Generic? Generic Makers Filed on the First Day the Law Allowed

  2026-10-04

• Is There a Zepbound Pill? No — Lilly's Pill Is a Different Drug, and Here Is the Record

  2026-10-04

• Do GLP-1 Pens Need to Be Refrigerated? Every Brand's Storage Rules, Read From the Labels

  2026-10-03

• Is Ozempic Insulin? Is Mounjaro? What GLP-1 Drugs Are, and Where Insulin Comes In

  2026-10-03

• Ozempic for Type 2 Diabetes: What the Trials Behind the Label Actually Showed

  2026-10-03

• What Is Zepbound? The Brand, What It Is Approved For, and How Its Label Has Changed Since 2023

  2026-10-04

• The Zepbound KwikPen: What the Label Says About the Four-Dose Pen, and How It Differs From the Single-Dose Pen

  2026-10-03

• Foundayo Cost 2026: Self-Pay Prices, the Savings Card's Caps and What a Year Really Costs

  2026-10-02

• Mounjaro Savings Card 2026: The $25 Card's Caps, the 3-Month Fill and Who Is Excluded

  2026-10-02

• NovoCare Pharmacy Explained: Who Actually Fills It, What It Charges, and the Rules in Its Terms

  2026-10-04

• Foundayo Review: What the Trial Registry and the Label Show About Results, Side Effects and Who Stopped

  2026-10-04

• Ozempic and Bone Loss: What the Labels, the Trials and Three 2026 Studies Actually Show

  2026-10-02

• Zepbound vs Ozempic: An Obesity Brand and a Diabetes Brand, Not Two Versions of One Drug

  2026-09-30

• Wegovy Pill Cost in 2026: $149 to $299 a Month, and What a Year Actually Costs

  2026-09-30

• LillyDirect Explained: What Lilly's Own Pharmacy Sells, Who Fills It and What It Costs

  2026-09-30

• Wegovy Pill Review: What the Trial Registry Shows, and the Daily Rule Users Live With

  2026-09-30

• Zepbound Savings Card 2026: The Three Cards, Their Caps and What They Exclude

  2026-10-04

• CVS Caremark and GLP-1 Coverage: Wegovy, Zepbound and Foundayo, Dated

  2026-09-28

• GLP-1 Drugs for Fatty Liver (MASLD and MASH): What the Biopsy Trials Found

  2026-09-28

• GLP-1 in Men vs Women: Weight Loss, Side Effects and Who the Trials Enrolled

  2026-09-28

• GLP-1 Prior Authorization: What Insurers Actually Require, Read From a Published Policy

  2026-09-28

• Maridebart Cafraglutide (MariTide): Amgen's Monthly GLP-1 Antibody, Read From Its Trials

  2026-09-28

• Amycretin (Now Zenagamtide): Novo Nordisk's One-Molecule GLP-1 and Amylin Drug, Read From Its Trials

  2026-09-27

• Survodutide vs Retatrutide: The Two Glucagon Drugs, Compared on Weight, Liver Fat and Heart Rate

  2026-09-27

• GLP-1 Drugs and Depression: What the Trials, the FDA and the Labels Say Now

  2026-09-27

• The GLP-1 Lawsuits: What the Federal Court Record Shows About the Ozempic, Wegovy and Mounjaro Cases

  2026-09-27

• GLP-1 vs GLP-3: There Is No Human GLP-3 — What the Name Means When Someone Is Selling It

  2026-09-27

• GLP-1 Alternatives: The Other Approved Weight-Loss Medicines and Surgery, From Their Own Labels

  2026-09-26

• The GLP-1 Weight-Loss Plateau: When It Arrives in the Trials, and What Has Been Tested After It

  2026-09-26

• Which GLP-1 Has the Fewest Side Effects? What the Head-to-Head Trials Show, and What the Labels Cannot

  2026-09-26

• How Long Does a GLP-1 Take to Work? The Four Clocks in the Labels and Trials

  2026-09-26

• GLP-1 Nausea: How Common It Is on Each Drug, When It Peaks, and How Long an Episode Lasts

  2026-09-26

• CagriSema: What Novo Nordisk's Amylin-Plus-Semaglutide Shot Did in Its Trials, and Where the FDA Review Stands

  2026-09-25

• GIP and GLP-1: Why One Drug Switches the GIP Receptor On, Another Blocks It, and Both Cause Weight Loss

  2026-09-25

• GLP-1 and Cancer: The Trials Say Little or No Effect, a Big Database Says Protection, and the Comparator Decides Which

  2026-09-25

• GLP-1 vs GLP-2: Same Gene, Same Gut Cells, Opposite Jobs — and Only One Is a Weight-Loss Drug

  2026-09-25

• Does GLP-1 Make You Tired? What Seven Labels Count, and Why Their Word "Fatigue" Means Five Different Things

  2026-09-25

• Foundayo vs Wegovy Pill: Two Labels Side by Side, and Why No One Can Say Which Works Better

  2026-09-24

• GLP-1 Benefits Beyond Weight: Every Approved Use, the Trial Behind It, and the Size of the Effect

  2026-09-24

• The Ozempic Pill: What Replaced Rybelsus, and the Wegovy Tablet It Matches

  2026-09-24

• Mounjaro Side Effects: The Diabetes Label's Record, With the Placebo Taken Out

  2026-09-24

• Ozempic Side Effects: The Label's Record, and the Eye Warning Nobody Explains

  2026-09-24

• Mounjaro vs Zepbound: The Same Tirzepatide, Two Labels, and a Nausea Rate That Doubles

  2026-10-04

• Trulicity vs Ozempic: The Only Head-to-Head Tested Doses Neither Label Tops Out At

  2026-09-23

• Ozempic Face: 32 Papers, One Measurement, and No Trial

  2026-09-23

• Wegovy Side Effects: The Label Now Counts Three Doses, and One Reaction Nobody Expected

  2026-10-04

• Zepbound Side Effects: One Label's Full Record, With the Placebo Taken Out

  2026-10-14

• The Cheapest GLP-1 Is Decided by Eligibility, Not by Drug

  2026-09-21

• Compounded GLP-1 Dosing: The Approved Class Was Designed So Nobody Measures

  2026-09-23

• Dose and Side Effects: What the Labels Show When the Placebo Is Taken Out

  2026-09-23

• Protein and GLP-1: The Trial That Would Settle It Reports in 2029

  2026-09-21

• ColonBroom's GLP-1 Booster: The Claims, and What Can Be Checked

  2026-09-21

• Which GLP-1 Causes the Most Weight Loss? The Posted Results, Ranked

  2026-09-20

• Compounded GLP-1s: The Word 'Shortage' Is Not in the Pharmacy Statute

  2026-09-20

• The Diet in the GLP-1 Trials: What Every Protocol Actually Prescribed

  2026-09-20

• How a GLP-1 Prescription Actually Happens: The Four Gates

  2026-09-23

• A Missed GLP-1 Dose: Ten Labels, No Two Worded the Same

  2026-09-20

• What a GLP-1 Costs Through Hers, and the Reversal Behind the Price

  2026-09-19

• What a GLP-1 Costs Through Ro, Read From the Manufacturers' Own Releases

  2026-09-19

• Every Approved GLP-1 Titration Schedule, Side by Side

  2026-09-24

• The Medicare GLP-1 Bridge: Who Qualifies, What It Pays, and the Four Ways It Can Cost You More

  2026-09-19

• Oral GLP-1s: Four Products, Two Chemistries, One Label That Says They Are Not Interchangeable

  2026-10-04

• GLP-1 Before and After: The Trial Record Is a Distribution, Not a Photograph

  2026-09-23

• GLP-1 Injections Explained: Same Three Sites, Seven Different Sets of Rules

  2026-10-03

• Is GLP-1 a Peptide? The Hormone Is. Three of the Drugs Are Not, and One Is 70 Times Heavier

  2026-09-18

• Is GLP-1 Safe? The Labels Answer a Narrower Question Than the One People Ask

  2026-10-04

• What Is a GLP-1? The Word Now Names Four Different Things

  2026-09-18

• GLP-1 Boosters: What the Sellers Claim, and the One Trial That Measured Neither GLP-1 Nor Weight

  2026-09-17

• GLP-1 Long-Term Side Effects: What Seven Trials Followed for Up to Seven Years Recorded

  2026-09-17

• GLP-1 Microdosing: A Market Practice With Three Registered Studies and No Results

  2026-09-24

• Is There an Over-the-Counter GLP-1? 436 FDA Listings, Zero Sold Without a Prescription

  2026-09-17

• How GLP-1 Works: Four Actions, and Why the Labels Describe Them Differently

  2026-09-17

• GLP-1 Overdose: Seven Labels, and Not One of Them Names a Number

  2026-09-23

• GLP-1 Patch Brands: A Dated Census of What Is Still Being Sold

  2026-09-16

• GLP-1 Patches: What They Contain, and the 4,114-Dalton Problem

  2026-09-16

• GLP-1 Supplements: The Trials That Exist, Including the One That Failed

  2026-09-16

• Natural GLP-1: Your Own Lasts 1.5 to 2 Minutes. That Is the Whole Story

  2026-09-23

• Which Drugs Are GLP-1s? The Question Has Three Answers, Not One

  2026-10-14

• GLP-1 Drugs and Pregnancy: The Same Molecule Gets a Different Instruction Depending on Which Brand Was Prescribed

  2026-10-04

• Semaglutide Reviews: The Trial Published a Standard Deviation, and It Is Bigger Than Most People's Result

  2026-09-23

• GLP-1 and Pancreatitis: Every Label Warns, and the One Brand That Counted It Against Placebo Found No Difference

  2026-09-23

• The GLP-1 Thyroid Cancer Warning: One Drug in the Class Grew Rat Tumours and Has No Boxed Warning, Another Grew None in Mice and Does

  2026-09-23

• When Will Ozempic Go Generic? The Compound Patent Runs to December 2031, and the Pen Patents Run to 2041

  2026-10-14

• Mounjaro vs Ozempic: Two Diabetes Labels Whose Wording Does Not Match Their Own Trials

  2026-09-23

• Wegovy vs Ozempic: The Same Molecule Under Four Separate FDA Applications

  2026-10-04

• GLP-1 Drugs and Menopause: The Word Does Not Appear in Any of the Four Labels

  2026-09-13

• GLP-1 Drugs and Sleep Apnoea: One Approved Indication, and the Patients Its Trials Left Out

  2026-09-13

• GLP-1 Drugs Before Surgery: The Label Declines to Give an Answer, and the Societies Disagree

  2026-09-13

• Zepbound vs Wegovy: Two Brands, Four Indications, and the Label That Decides Everything

  2026-09-23

• GLP-1 Pill vs Injection: One Molecule Is Approved Both Ways, and the Comparison Is Not Close

  2026-09-23

• Semaglutide vs Liraglutide: Seven Times the Injections for Less Than Half the Result

  2026-10-17

• GLP-1 for PCOS: Thirty-One Studies, No Approved Indication, and Not One Industry Sponsor

  2026-09-11

• GLP-1 Insurance Coverage: The Law Excludes These Drugs by Use, Not by Drug

  2026-09-23

• GLP-1 Gallbladder Risk: The Drug That Causes the Most Weight Loss Has the Smallest Gallstone Signal

  2026-09-23

• Tirzepatide Reviewed: The Trial Numbers, and the Complaint Nobody Counts

  2026-09-23

• GLP-1 Side Effects: What the Labels Count, and the One Number That Matters

  2026-09-23

• GLP-1 Hair Loss: The Same Molecule Counts It in One Label and Not the Other

  2026-09-23

• GLP-1 Muscle Loss: One Sentence in the Label, Nine Trials Trying to Fix It

  2026-09-23

• Stopping a GLP-1: What Two Randomised Withdrawal Trials Actually Measured

  2026-09-10

• Costco GLP-1 Prices: $349 at the Pharmacy, Not in the Sesame Benefit

  2026-10-06

• What Hims & Hers Charges for a GLP-1, and What Its Filings Say

  2026-09-19

• Noom GLP-1 Cost: The $79 Headline and the $199 Footnote

  2026-09-09

• WeightWatchers GLP-1 Cost: The $74 Buys No Medication

  2026-09-09

• Mochi Health Review: What the $60 Price Actually Buys

  2026-09-09

• What Mounjaro Costs in 2026, and the List Price Hidden in Its Own Savings Card

  2026-09-23

• What Ozempic Costs in 2026, and Why It Costs More Than Wegovy

  2026-09-28

• What Wegovy Costs in 2026: Every Dose, Every Route, Dated

  2026-10-04

• What Zepbound Costs in 2026, and the 45-Day Rule Behind the Cheapest Price

  2026-09-30

• GLP-1 Medicines and Alcohol: What the Trials Found, and What the Labels Say

  2026-09-23

• Compounded Semaglutide in 2026: What Replaced It

  2026-09-07

• Orforglipron vs Tirzepatide: A Daily Pill Against a Weekly Injection

  2026-10-02

• Survodutide vs Tirzepatide: Reading a Brand-New Phase 3 Against an Approved Drug

  2026-09-06

• Tirzepatide vs Semaglutide: The One Trial That Compared Them Directly

  2026-09-06

• GLP-1 Pills in 2026: What the Two Approved Tablets Cost, and What They Do

  2026-09-24

• What the GLP-1 Brain Research Actually Found

  2026-09-05

• Compounded Tirzepatide vs Zepbound: What Changed When the Shortage Ended

  2026-09-05

• Retatrutide vs Tirzepatide: What the Trials Show, and What Is Not Known Yet

  2026-09-05

• How Much Do GLP-1 Medicines Cost in 2026? Every Price, Dated

  2026-09-28

• Retatrutide: Approval Status, Trial Doses, Results and What Is Being Sold Under Its Name

  2026-09-05

glp1ledger is operated by Sherdas LLC. How this site works.